1315 Capital

1315 Capital provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies, the latter including businesses focused on cost containment and digital health. We believe that these investment areas are attractive largely due to numerous niche market sub-segments and business models where high-quality management teams can rapidly grow small platform companies, in a capital efficient way, into large and important businesses. The firm targets $10-$20 million investments in commercial healthcare entities that have the potential to scale to approximately $100 million of revenue, a highly attractive level for acquisition or to access the public markets.

Edward Chan

Partner

Carter Cortazzi

Associate and Investment Team Member

Michael Koby

Co-Founder and Partner

Li, Ian B.

Principal

Craig Matturro

Principal

Matthew Reber

Partner

11 past transactions

NutriSense

Series A in 2022
NutriSense is a health and wellness platform that monitors blood glucose levels in real-time with CGM and a tracking app. It personalizes nutrition by leveraging state-of-the-art continuous glucose monitoring and machine learning technology. The company's mission is to help anybody discover and reach their health potential. NutriSense was founded in 2019 and is based in Chicago, Illinois.

Onkos Surgical

Series C in 2021
Onkos Surgical is a privately-held surgical oncology company that brings new technology and solutions to surgical oncologists. It has been revolutionizing how musculoskeletal cancer and complex orthopedic conditions are treated. Its personalized approach supports improved patient outcomes and experiences using the latest innovations in virtual surgical planning, 3D modeling and printing, implant design, and workflow optimization.

miraDry

Acquisition in 2021
miraDry is a only FDA cleared device to reduce underarm sweat, odor and permanently reduce hair of all colors. miraDry non-invasive procedure is safe and highly efficacious with a proven commercial and clinical track record.

Encore Dermatology

Debt Financing in 2019
Encore Dermatology is a privately held fully-integrated dermatology company that provides prescription therapies and medical devices to dermatologists. It provides a range of medical dermatology products, treating a number of topical disease states that enable patients to get improved skin care and treatment with ease. Encore Dermatology was established in 2015 and is headquartered in Malvern, Pennsylvania.

Biocoat

Acquisition in 2019
Biocoat is a developer of biomaterial coatings for medical devices that are custom engineered to meet client design parameters. Its specialty is supplying lubricious hydrophilic coatings for medical devices.

Centurion Service Group

Acquisition in 2018
Centurion Service Group has grown to become the largest used medical equipment auction house in the world, with warehouse locations in Chicago, Las Vegas, South Florida, and Dallas. Medical equipment buyers from around the world know to go to Centurion’s auctions for all their hospital equipment purchasing needs, including radiology, anesthesia, lab, exam, patient monitoring, cardiology, endoscopy, surgery, instrumentation, disposables, and much more. With over 8,000 pieces of surplus medical equipment sold every month, it’s ideal as a single source for acquiring the wide range of used medical equipment they need and in the quantities they desire.

Misonix

Post in 2017
Misonix has long been at the forefront of ultrasound technology and is a world leader in the design, development, manufacturing, and marketing of ultrasonic surgical devices. Their innovative, ultrasonic platforms for surgical applications include aspirators for the removal of both soft and hard tissue, instruments for laparoscopic cutting and coagulation, devices for wound cleansing and debridement, products for precision bone cutting and sculpting, liposuction instrumentation for improving body aesthetics, and High Intensity Focused Ultrasound (HIFU) systems for the ablation of tumors.

Colorescience

Series C in 2017
Colorescience is a luxury aesthetic makeup line in the medical and resort spa channel, differentiating their products from other makeup lines through high quality, efficacious ingredients, luxury colores and formulations, and convenience and simplicity of use. With every product the company strives to make a difference in the diminution of skin cancer and skin conditions.

Onkos Surgical

Series B in 2017
Onkos Surgical is a privately-held surgical oncology company that brings new technology and solutions to surgical oncologists. It has been revolutionizing how musculoskeletal cancer and complex orthopedic conditions are treated. Its personalized approach supports improved patient outcomes and experiences using the latest innovations in virtual surgical planning, 3D modeling and printing, implant design, and workflow optimization.

JDS Therapeutics

Private Equity Round in 2015
JDS develops, patents and commercializes natural, bioactive compounds. JDS owns more than 100 issued and pending patents.

Onkos Surgical

Series A in 2015
Onkos Surgical is a privately-held surgical oncology company that brings new technology and solutions to surgical oncologists. It has been revolutionizing how musculoskeletal cancer and complex orthopedic conditions are treated. Its personalized approach supports improved patient outcomes and experiences using the latest innovations in virtual surgical planning, 3D modeling and printing, implant design, and workflow optimization.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.